APAC Digital Pathology Market

APAC Digital Pathology Market Size (2022 to 2027)

The digital pathology market size in the Asia Pacific region is forecasted to grow USD 125.24 million by 2027 from USD 73.89 million in 2022, growing at a CAGR of 11.13% from 2022 to 2027.

Artificial intelligence in digital pathology can transform the patient experience with equipment and apps that provide access to electronic health records, radiology images, and other information, allowing patients to actively participate in the treatment process, which is expected to boost the APAC digital pathology market during the forecast period. In addition, unhealthy diet, cigarette smoking, binge drinking, and inadequate physical activity are among the primary noncommunicable illnesses caused by modifiable behavioral risk factors; demographic factors such as urbanization, population aging, and the need for higher-quality healthcare are further estimated to contribute to the market's growth.

Lockdowns and social distance restrictions have been implemented as a result of the COVID-19 pandemic. Such limits have boosted demand for digital pathology systems, which allow pathologists to see diagnostic results remotely for primary diagnosis. In addition, the desire for quicker diagnostic tools for chronic diseases like cancer and an increased focus on increasing workflow efficiency have been significant drivers to the APAC digital pathology market.

Countries' authority allows medical device firms to pursue various marketing strategies and provides several options for product segmentation. As a result, the digital pathology market in Asia-Pacific is projected to expand in the near future. Computer-aided diagnosis, which combines image processing, physics, mathematics, and computing algorithms, aids in disease identification and evaluation of anatomic structures of interest and disease progression quantification and risk assessment. In the near future, these advantages are expected to fuel demand for digital pathology systems. In addition, the growing incidence of chronic diseases is expected to increase clinical urgency to adopt digital pathology to improve existing inadequate patient diagnostic imaging measures and lower high costs associated with traditional diagnostic imaging.

The high costs associated with these systems are likely to restrict their adoption. In addition, lack of trained personnel, limited adoption due to the availability of traditional pathology, technophobic pathologists' mentalities, image storage concerns due to extensive data, reimbursement issues, and a limited clinical test menu are expected to challenge digital pathology's adoption in this region.

This research report on the APAC digital pathology market has been segmented and sub-segmented into the following categories:

By Type: 

• Human Digital Pathology
• Animal Digital Pathology

By Product: 

• Scanners
• Software
• Communication Systems
• Storage Systems

By Application: 

• Teleconsultation
• Diseases Diagnosis
• Drug Discovery
• Training
• Education

By End User: 

• Pharmaceutical Companies
• Hospitals
• Academic Institutions

By Country: 

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC

Geographically, the digital pathology market in the APAC region is expected to register the most substantial share in the global market during the forecast period. Due to rising healthcare expenditure, the need for efficient and cost-effective equipment, and growth in healthcare infrastructure, the Asia-Pacific region is anticipated to grow rapidly in the digital pathology market. As the region's population grows, so will the demand for healthcare systems, which will benefit Asia-Pacific digital pathology. The unfilled need of healthcare systems will provide an opportunity to implement digital healthcare applications and electronic health records (EHR). Furthermore, the APAC eHealth market is evolving due to the growing trend of telehealth and mobile health. Because of the rising prevalence of cancer, which affects a vast population, the Asia Pacific healthcare industry has significantly impacted the market. Additionally, an increasing desire for innovative treatment alternatives, improved patient care facilities, and lower laboratory costs are likely to fuel demand.

The Indian digital pathology market is predicted to be growing at a CAGR of 13.4% from 2022 to 2027 and has significant potential. India has a massive patient pool suffering chronic diseases, one of the primary drivers promoting the Indian market.

The digital pathology market in China is forecasted to register a CAGR of 10.12% during the forecast period. Ningbo Konfoong Bioinformation Tech Co., Ltd. is one of the local players in the China market and accounting for a significant share in the Chinese market.

The Japanese digital pathology market is one of the fastest-growing regional markets in Asia-Pacific and is estimated to showcase a CAGR of 9.8% from 2022 to 2027.

Although digital pathology is still in its nascent stage in Indonesia, it is projected to develop rapidly. It offers an enormous opportunity as clinical laboratories undergo significant transformations in their use of high-tech and automation. Furthermore, hospitals and clinical laboratories are motivated to adopt digital pathology systems to provide a seamless treatment pathway and exhibit high throughput capacity and efficiency.

KEY MARKET PLAYERS:

Companies such as Perkin Elmer, Inc., Definiens AG, Sectra AB, Koninklijke Philips N.V, GE Healthcare, Inspirata Co., Ventana Medical Systems, Inc., Leica Biosystems, 3D-Histech Ltd, Hamamatsu Photonics K.K., Digipath Co., ZEISS, Olympus Corporation, Yokogawa Electronics Corporation and Quorum Technologies Inc. are playing a promising role in the APAC Digital Pathology Market.

Key market players are entering into partnerships, mergers, and acquisitions, and well-planned distribution strategies to capitalize on the overall opportunities present in untapped markets.